Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Ludiomil; Belgium: Ludiomil; Bulgaria: Ludiomil; Cyprus: Epalon; Czech Republic: Ludiomil; Denmark: Ludiomil; France: Ludiomil; Germany: Ludiomil, Maprolu, Maprotilin; Greece: Ludiomil; Hungary: Ludiomil; Italy: Ludiomil; Luxembourg: Ludiomil, Maprolu; Malta: Epalon, Ludiomil; Netherlands: Maprotiline; Poland: Ludiomil; Portugal: Ludiomil; Romania: Ludiomil; Slovakia: Ludiomil; Slovenia: Ladiomil; Spain: Ludiomil; Sweden: Ludiomil, Maprotilin.

North America

Canada: Maprotiline; USA: Maprotiline.

Latin America

Brazil: Ludiomil; Mexico: Ludiomil.


Japan: Cronmolin, Ludiomil, Mapromil, Neuomil.

Drug combinations


Maprotiline Hydrochloride: C~20~H~23~N HCl. Mw: 313.86. 9,10-Ethanoanthracene-9(10H)-propanamine, N-methyl-, hydrochloride. CAS-10347-81-6.

Pharmacologic Category

Antidepressants; Tricyclics and Other Norepinephrine-reuptake Inhibitors. (ATC-Code: N06AA21).

Mechanism of action

Mechanism of action in management of depressive and anxiety disorders might involve inhibition of norepinephrine reuptake. Exhibits anticholinergic activity and sedative properties.

Therapeutic use

Treatment of depression and anxiety associated with depression.

Pregnancy and lactiation implications

Unlabeled use

Bulimia. Duodenal ulcers. Enuresis. Urinary symptoms of multiple sclerosis. Pain. Panic attacks. Tension headache. Cocaine withdrawal.


Hypersensitivity to maprotiline or any component of the formulation. Use of MAOIs within 14 days. Use in during acute recovery phase of myocardial infarction.

Warnings and precautions

Antidepressants increase risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Maprotiline not FDA approved for use in children. Might worsen psychosis in some patients or precipitate shift to mania or hypomania in bipolar disorder. Maprotiline not FDA approved for treatment of bipolar depression. Might cause anticholinergic effects (blurred vision, constipation, urinary retention, xerostomia)(use with caution in decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems). Might cause orthostatic hypotension (use with caution in cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). Might cause sedation. Use with caution in history of cardiovascular disease (including previous myocardial infarction, stroke, tachycardia, or conduction abnormalities). Use with caution in hepatic and renal impairment. Use with caution in risk of seizures, including patients with history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Use with caution in hyperthyroidism or patients receiving thyroid supplementation. Effects may be potentiated when used with other sedative drugs or ethanol. Use with caution in the elderly. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods. Might increase risks associated with electroconvulsive therapy.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart